%0 Journal Article
%T Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
%A Marco Innamorati
%A Stefano Baratta
%A Cristina Di Vittorio
%A David Lester
%A Paolo Girardi
%A Maurizio Pompili
%A Mario Amore
%J Schizophrenia Research and Treatment
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/423205
%X Objectives. The aim of this naturalistic study was to investigate whether treatment with clozapine and other atypical antipsychotics for at least 2 years was associated with a reduction in psychotic and depressive symptoms and an improvement in chronic schizophrenia patients＊ awareness of their illness. Methods. Twenty-three adult outpatients (15 men and 8 women) treated with clozapine and 23 patients (16 men and 7 women) treated with other atypical antipsychotics were included in the study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms were assessed with the Calgary Depression Scale for Schizophrenia (CDSS), and insight was assessed with the Scale to Assess Unawareness of Mental Disorder (SUMD). Results. The sample as a whole had a significant reduction in positive, negative, and general symptoms, whereas the reduction in depression was significant only for patients with CDSS scores of 5 and higher at the baseline. At the follow-up, patients treated with other atypical antipsychotics reported a greater reduction in depression than patients treated with clozapine, but not when limiting the analyses to those with clinically relevant depression. Conclusions. Atypical antipsychotics may be effective in reducing psychotic and depressive symptoms and in improving insight in patients with chronic schizophrenia, with no differences in the profiles of efficacy between compounds. 1. Introduction Schizophrenia is a serious and disabling mental disorder usually associated with a decline in social and occupational functioning, and deficits in communication, control of behavior, the ability to feel pleasure, will, and initiative. The disease affects approximately 1% of the world＊s population, or around 1每12 adults in every 1,000, mostly in the 15每35 year-old group [1每3]. Yearly incidence is 16每40 cases per 100,000 according to the ICD-9 criteria and 7每14 cases per 100,000 using more restrictive criteria [4, 5]. The risk of developing schizophrenia during a lifetime is around 0.7% (95% confidence interval (CI): 0.3%每2.0%) [3]. The longitudinal course of schizophrenia is characterized by recurrent episodes of illness, periods of complete or partial remission, and often chronicity. Schizophrenia is linked to functional and social disability, it impacts the patients＊ ability to engage in productive work and social relationships, and it is associated with a reduced life expectancy as a result of accidents, high comorbidity with medical conditions, and suicide [6每17]. Furthermore, depression in schizophrenic
%U http://www.hindawi.com/journals/schizort/2013/423205/